AI Summary
Participants in the pembrolizumab plus chemotherapy group had a significant improvement in overall survival compared with the placebo plus chemotherapy group. Pembrolizumab with chemotherapy may be a first-line treatment option for patients with certain types of gastric or gastro-esophageal junction cancer.
Participants in the pembrolizumab plus chemotherapy group had a significant and clinically meaningful improvement in overall survival with manageable toxicity compared with participants in the placebo plus chemotherapy group. Therefore, pembrolizumab with chemotherapy might be a first-line treatment option for patients with locally advanced or metastatic HER2-negative gastric or gastro-esophageal junction adenocarcinoma.